Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Down Syndrome Children With AML and MDS Under the Age of 4 Years
NCT00369317Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Children's Oncology Group. Primary endpoints: Event-free Survival at 3 years and Overall Survival at 3 years. Started Mar 2007; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00369317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369317.